Brochure available! Pharmacovigilance training V edition, Madrid & Online 27-28 May 2024
PVpharm is leading the way in pharmacovigilance training by innovatively organizing another edition of its Pharmacovigilance Training.
Pharmacovigilance training V edition, Madrid & Online 27-28 May 2024
PVpharm is leading the way in pharmacovigilance training by innovatively organizing another edition of its Pharmacovigilance Training.
Defafios actuais de Farmacovigilancia
José Alberto Ayala Ortiz, CEO of PVpharm participated in the 1st edition of the Conference organized by OWL Pharma, Desafios Actuais de Farmacovigilancia, held in Lisbon on the 22nd of November 2023. José provided insight about Signal Detection in Pharmacovigilance and the use of EVDAS. Please check OWL Pharma website for more information: https://www.owlpharma.pt/news/o-futuro-de-farmacovigilancia-1a-edicao-desafios-atuais-de-farmacovigilancia **PVpharm is also organizing in-house training in pharmacovigilance for pharmaceutical companies and CROs, please contact us for further information.**
IV PV TRAINING: unique pharmacovigilance training experience
PVpharm led the way in pharmacovigilance training by innovatively organizing another edition of its Pharmacovigilance Training. This 3rd edition was hosted on May, 2022.
Faculty at Signal Management training by DIA June 2023
On 12-15 June 2023, José Ortiz provided the training faculty for the Signal Management training organized by DIA. This training provides knowledge over Signal Management to the participants, so they can apply the basic concepts and principles of signal detection in pharmacovigilance, from simple visualisation and tabulation methods to sophisticated data mining techniques. • Design the signal management process for institutions and companies of various sizes, portfolios and geographical presence, based on the possibilities and limitations of their data and resources • Understand key messages from the current European and US regulations on signal management, to best manage implications also…
Faculty at Signal Management training by DIA November 2022
On 21-24 November 2022, José Ortiz provided the training faculty for the Signal Management training organized by DIA. This training provides knowledge over Signal Management to the participants, so they can apply the basic concepts and principles of signal detection in pharmacovigilance, from simple visualisation and tabulation methods to sophisticated data mining techniques. • Design the signal management process for institutions and companies of various sizes, portfolios and geographical presence, based on the possibilities and limitations of their data and resources • Understand key messages from the current European and US regulations on signal management, to best manage implications also…
PVpharm to present a key trending subject at Farmaforum 2022
In the next edition (October 2022), PVpharm will not only participate as an exhibitor but also as a speaker, leading one of the conferences of this benchmark event.
III PV TRAINING: Leading experts make success possible
PVpharm led the way in pharmacovigilance training by innovatively organizing another edition of its Pharmacovigilance Training. This 3rd edition was hosted on May, 2022.
Time to meet in person again: PV TRAINING III EDITION
PVpharm organizes its successful Pharmacovigilance Training. This 3rd edition will be hosted in Madrid on May 30 and 31, 2022, with the option of attending online.
Jose Ortiz at the European Pharmacovigilance Congress 2020
We are delighted to announce that José Alberto Ayala Ortiz, PVpharm's CEO, will be participating in the European Pharmacovigilance Congress 2020 organized by the Pharma Education Center. You can find the link to the Congress here: https://www.pharmaeducationcenter.it/wp-content/uploads/2020/11/EUPV_Final_2020-1.pdf José will be participating in two round tables on the 27th of November:-Eudravigilance EVDAS updates-Local VS Global PV regulations Please see some screenshots of the sessions: PVpharm is also organizing in-house trainings in pharmacovigilance for pharmaceutical companies and CROs, please contact us for further information.